ARNA: Arena Pharmaceuticals, Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 7, 12:45 PM Arena Pharmaceuticals (ARNA +8.2%) ramps higher today as the company moves closer than it's ever been to bringing its obesity drug Belviq to the U.S. market. A notice on the DEA's website says regulators have approved the scheduling of Belviq as a controlled substance. The notice will be published in the Federal Register tomorrow, and Belviq can be sold 30 days after. 3 Comments [Healthcare, On the Move]
Friday, May 3, 9:10 AM Premarket gainers: PKT +32%. YRCW +27%. INVN +18%. YY +8%. DDD +5%.
Losers: VCRA -35%. ZAGG -24%. GUID -23%. CHE -16%. ARNA -13%. CETV -13%. HMY -9%. LNKD -9%. AGNC -6%. RBS -6%. 3 Comments [On the Move]
Thursday, May 2, 6:10 PM After-hours top gainers, as of 5:15 p.m.: PKT +23%. BCOR +12%. INVN +8%. FORM +7%. FLT +6%.
After-hours top losers: ZAGG -26%. VCRA -26%. GUID -20%. ARNA -15%. BRKR -11%. Comment! [On the Move]
Thursday, May 2, 6:06 PM More on Arena Pharmaceuticals (ARNA): Q1 misses EPS estimates badly, but adding to an afternoon beating by investors is the company's disclosure that it's withdrawn a regulatory application to sell its weight-loss Belviq therapy in the European Union after calculating it wouldn't get a positive decision. Shares -15.7% AH. Comment! [Earnings, Healthcare, On the Move, Global & FX]
Thursday, May 2, 4:37 PM Arena Pharmaceuticals (ARNA): Q1 EPS loss of $0.09 misses by $0.20. Revenue of $2.4M (-9% Y/Y). (PR). Shares -11.7% AH. 4 Comments [Healthcare, Earnings, On the Move, Breaking News]
Thursday, May 2, 12:10 AM Notable earnings after Thursday’s close: ACLS, ACTV, ADNC, AGNC, AIG, ALSK, AREX, ARNA, ATHN, BBG, BCOR, BERY, BRKR, CBI, CNQ, DNB, DOLE, DRIV, EGO, ELON, ELX, FBHS, FLR, FLT, GEOS, GHDX, GILD, GMED, GTY, HAIN, HI, HMA, HTGC, INVN, KOG, KRFT, LNKD, MKH, MTZ, MYL, NBIX, NFG, NILE, NSR, ONNN, OPEN, PKT, PWER, QLGC, SKUL, SPF, SPWR, SWN, TDC, THOR, TPX, TSYS, TTMI, WTW, WWWW, XL, ZAGG Comment! [Earnings]
Wednesday, May 1, 5:35 PM Notable earnings after Thursday’s close: ACLS, ACTV, ADNC, AGNC, AIG, ALSK, AREX, ARNA, ATHN, BBG, BCOR, BERY, BRKR, CBI, CNQ, DNB, DOLE, DRIV, EGO, ELON, ELX, FBHS, FLR, FLT, GEOS, GHDX, GILD, GMED, GTY, HAIN, HI, HMA, HTGC, INVN, KOG, KRFT, LNKD, MKH, MTZ, MYL, NBIX, NFG, NILE, NSR, ONNN, OPEN, PKT, PWER, QLGC, SKUL, SPF, SPWR, SWN, TDC, THOR, TPX, TSYS, TTMI, WTW, WWWW, XL, ZAGG Comment! [Earnings]
Friday, April 5, 12:06 PM Arena Pharmaceuticals (ARNA -1.8%) loses steam with the rest of the overall market despite its announcement that it was initiating dosing in a Phase 1 clinical trial of APD334, a potential treatment of autoimmune diseases. The trial is set to evaluate safety, tolerability and pharmacokinetics of single-ascending doses of APD334 in up to 64 volunteers. 1 Comment [Healthcare, On the Move]
Monday, April 1, 11:51 AM Shares in Arena Pharmaceuticals (ARNA -2.2%) turn south this morning, shrugging off an earlier announcement of a $500K milestone payment from Eisai on the submission of a marketing authorization application for Belviq with regulatory authorities in Mexico. About 30% of adults in Mexico are obese and 70% are overweight or obese, which the company says is leading to a significant health and economic burden in the country. Comment! [Healthcare, On the Move, Global & FX]
Thursday, March 28, 5:21 PM Bacteria that live in the gut change after gastric-bypass surgery and may aid in weight loss, according to a recent study. Gastric surgery helps people lose weight by shrinking the size of the stomach and making it tougher to absorb calories, now scientists think it may also adjust gastrointestinal bacteria, contributing to weight loss and raising the possibility for less-drastic obesity treatment. 7 Comments [Healthcare]
Friday, March 22, 5:44 PM After-hours top gainers, as of 5:15 p.m.: SFD +6%. REGI +6%. GTI +4%. FIVE +4%. KWK +4%.
After-hours top losers: IDIX -10%. TTS -6%. SVU -4%. MTG -3%. ARNA -2%. 3 Comments [On the Move]
Monday, March 4, 10:33 AM Vivus (VVUS -2.5%) slides on concerns that it may be lowering the price of Qsymia just months after commercial marketing began. Bloomberg's Andrew Berens says the company will start offering 30-days of medium-dose Qsymia for maximum out-of-pocket cost of $75, which is 70% below the current price. The move could pose risks for Arena's (ARNA -4.4%) Belviq, which is a competitor to Qsymia. 6 Comments [Healthcare, On the Move]
Monday, March 4, 8:15 AM More on Arena Pharmaceutical (ARNA -1.7%) Q4: In addition to revenues from Belviq sales, Arena expects $66.5M in milestone payments from marketing and distribution partner Eisai in 2013, $6M from amortization of upfront payments, and $3M from manufacturing services from Siegfried. Arena also expects R&D costs of $70-78M and G&A expenses of $28-34M. (PR) Comment! [Healthcare, Earnings]
Monday, March 4, 7:09 AM Arena Pharmaceutical (ARNA): Q4 EPS of -$0.10 misses by $0.05. Revenue of $1.94M (-9.5% Y/Y). (PR) 2 Comments [Earnings, Breaking News, Healthcare]
Monday, March 4, 12:05 AM Notable earnings before Monday’s open: ARNA, BYD, CEL, SSYS, YGE 2 Comments [Earnings]
Sunday, March 3, 5:30 PM Notable earnings before Monday’s open: ARNA, BYD, CEL, SSYS, YGE Comment! [Earnings]

ARNA Arena Pharmaceuticals, Inc.

ARNA

Arena Pharmaceuticals, Inc.